文献速递临床试验与 GCP流行病学与生物统计

艾司西酞普兰治疗急性冠脉综合征后抑郁对长期心脏结局的影响:随机临床试验

Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

该随机双盲安慰剂对照试验纳入300例近期急性冠脉综合征(ACS)伴抑郁患者,比较艾司西酞普兰与安慰剂治疗24周对长期主要不良心脏事件(MACE)的影响。

要点

  • 艾司西酞普兰治疗24周可降低近期ACS伴抑郁患者长期MACE风险(HR 0.69)。
  • 心肌梗死风险显著降低(HR 0.54),全因死亡、心源性死亡及PCI风险无显著差异。
  • 需进一步研究评估该发现的普适性。

核心结论

  • 在近期ACS伴抑郁患者中,与安慰剂相比,艾司西酞普兰治疗24周后经中位8.1年随访观察到MACE风险降低。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在韩国光州全南大学医院纳入300例近期ACS伴抑郁患者,2007年5月至2013年3月入组,2017年6月完成随访。
  • 患者随机接受艾司西酞普兰(5、10、15或20 mg/d灵活剂量,n=149)或匹配安慰剂(n=151)治疗24周。

关键数值与推荐

  • 主要终点MACE为全因死亡、心肌梗死和经皮冠状动脉介入治疗(PCI)的复合终点。
  • 300例随机患者平均年龄60岁,女性119例(39.3%),100%完成中位8.1年(四分位距7.5-9.0)随访。

临床怎么用

  • 对近期ACS伴抑郁患者,可考虑使用艾司西酞普兰治疗以改善长期心脏预后。
  • 治疗决策需结合个体情况,并关注艾司西酞普兰对心肌梗死风险的潜在获益。

局限性

  • 研究仅纳入韩国单中心患者,结论外推需谨慎,需进一步研究评估普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Depression has been associated with poorer medical outcomes in acute coronary syndrome (ACS), but there are few data on the effects of antidepressant treatment on long-term prognosis. OBJECTIVE: To investigate the effect on long-term major adverse cardiac events (MACE) of escitalopram treatment of depression in patients with recent ACS. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted among 300 patients with recent ACS and depression enrolled from May 2007 to March 2013, with follow-up completed in June 2017, at Chonnam National University Hospital, Gwangju, South Korea. INTERVENTIONS: Patients were randomly assigned to receive either escitalopram in flexible dosages of 5, 10, 15, or 20 mg/d (n = 149) or matched placebo (n = 151) for 24 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was MACE, a composite of all-cause mortality, myocardial infarction (MI), and percutaneous coronary intervention (PCI). Four secondary outcomes were the individual MACE components of all-cause mortality, cardiac death, MI, and PCI. Cox proportional hazards models were used to compare the escitalopram and placebo groups by time to first MACE. RESULTS: Among 300 randomized patients (mean age, 60 years; 119 women [39.3%]), 100% completed a median of 8.1 (interquartile range, 7.5-9.0) years of follow-up. MACE occurred in 61 patients (40.9%) receiving escitalopram and in 81 (53.6%) receiving placebo (hazard ratio [HR], 0.69; 95% CI, 0.49-0.96; P = .03). Comparing individual MACE outcomes between the escitalopram and placebo groups, respectively, incidences for all-cause mortality were 20.8% vs 24.5% (HR, 0.82; 95% CI, 0.51-1.33; P = .43), for cardiac death, 10.7% vs 13.2% (HR, 0.79; 95% CI, 0.41-1.52; P = .48); for MI, 8.7% vs 15.2% (HR, 0.54; 95% CI, 0.27-0.96; P = .04), and for PCI, 12.8% vs 19.9% (HR, 0.58; 95% CI, 0.33-1.04; P = .07). CONCLUSIONS AND RELEVANCE: Among patients with depression following recent acute coronary syndrome, 24-week treatment with escitalopram compared with placebo resulted in a lower risk of major adverse cardiac events after a median of 8.1 years. Further research is needed to assess the generalizability of these findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00419471.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Kim JM, Stewart R, Lee YS, et al. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. JAMA. 2018. PMID: 30043065. doi:10.1001/jama.2018.9422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。